|
70 Companies |
|
97 Products |
|
97 Products |
|
124 Mechanisms of Action |
|
1 Trial |
|
1962 News |
|
| 12345678910111213...3940» |
- | Phase classification: Group Therapy for Women Prisoners With Comorbid Substance Use and Depression (clinicaltrials.gov) - Mar 20, 2025
P=N/A, N=38, Completed, Sponsor: Brown University
Phase classification: P2 --> P=N/A
- | Phase classification: Treating Tobacco Dependence in Inpatient Psychiatry - 1 (clinicaltrials.gov) - Apr 11, 2024
P=N/A, N=224, Completed, Sponsor: Stanford University
Phase classification: P2 --> P=N/A Phase classification: P2 --> P=N/A
- | NN1213 / Novo Nordisk
Trial termination: Assessing the Fit of Motivational Interviewing by Cultures With Adolescents (clinicaltrials.gov) - Jan 8, 2024
P=N/A, N=506, Terminated, Sponsor: University of New Mexico
Phase classification: P2 --> P=N/A Completed --> Terminated; Not an Applicable Clinical Trial (ACT).
- | Enrollment change: ADVISE: Alcohol Drinking as a Vital Sign (clinicaltrials.gov) - Apr 24, 2019
P=N/A, N=639613, Completed, Sponsor: Kaiser Permanente
Completed --> Terminated; Not an Applicable Clinical Trial (ACT). N=466000 --> 639613
- | Trial completion: Integrated Intervention for Substance Abusers With Depressive Disorders (clinicaltrials.gov) - Apr 20, 2019
P2, N=276, Completed, Sponsor: VA Office of Research and Development
N=466000 --> 639613 Terminated --> Completed
- | Phase classification: Contingency Management for Chronic Recidivist Alcohol-Dependent Patients (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=104, Completed, Sponsor: UConn Health
Terminated --> Completed Phase classification: P1/2 --> P=N/A
- | Trial completion, Enrollment change: Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=40, Completed, Sponsor: Albert Einstein College of Medicine
Phase classification: P1/2 --> P=N/A Recruiting --> Completed | N=100 --> 40
- | Trial completion: Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=8, Completed, Sponsor: University of Virginia
Recruiting --> Completed | N=100 --> 40 Active, not recruiting --> Completed
- | Trial completion: Exercise: Addressing Stress in Relapse Prevention for Substance Use Disorders (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=147, Completed, Sponsor: St. Louis University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | GET 73 / CT Pharmaceutical Laboratory
Trial completion date, Trial primary completion date: SPAD: Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent (clinicaltrials.gov) - Apr 20, 2019
P1b/2a, N=25, Completed, Sponsor: Laboratorio Farmaceutico Ct S.r.l.
Active, not recruiting --> Completed Trial completion date: Feb 2018 --> Nov 2018 | Trial primary completion date: Feb 2018 --> Nov 2018
- ||| NN1213 / Novo Nordisk
Trial completion: DHM&NAS: Donor Human Milk in Neonatal Abstinence Syndrome (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=12, Completed, Sponsor: Neolac Inc dba Medolac Laboratories
Trial completion date: Feb 2018 --> Nov 2018 | Trial primary completion date: Feb 2018 --> Nov 2018 Active, not recruiting --> Completed
- | Phase classification: Tobacco Dependence Treatment for Asian Americans (clinicaltrials.gov) - Mar 13, 2019
P=N/A, N=109, Completed, Sponsor: University of Massachusetts, Boston
Active, not recruiting --> Completed Phase classification: P1/2 --> P=N/A
- | Trial completion: ADVISE: Alcohol Drinking as a Vital Sign (clinicaltrials.gov) - Mar 13, 2019
P=N/A, N=466000, Completed, Sponsor: Kaiser Permanente
Phase classification: P1/2 --> P=N/A Active, not recruiting --> Completed
- Trial completion date: To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure (clinicaltrials.gov) - Feb 19, 2019
P3, N=18, Terminated, Sponsor: Vital Therapies, Inc.
Active, not recruiting --> Completed Trial completion date: Oct 2015 --> Sep 2018
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Reflex: Pupillometry: Pupil Response in Patients on Opioids. (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=63, Completed, Sponsor: Oslo University Hospital
Trial completion date: Oct 2015 --> Sep 2018 Not yet recruiting --> Completed | N=100 --> 63 | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Dec 2015 --> Aug 2018
- | NN1213 / Novo Nordisk
Trial completion: A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers (clinicaltrials.gov) - Jan 17, 2019
P=N/A, N=30, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Completed | N=100 --> 63 | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Dec 2015 --> Aug 2018 Active, not recruiting --> Completed
- | acetylcysteine solution / Generic mfg.
Enrollment change: Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1 (clinicaltrials.gov) - Jan 16, 2019
P2, N=111, Completed, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed N=235 --> 111
- | Trial completion: Treatment of Alcohol Dependence and Comorbid Bipolar Disorder (clinicaltrials.gov) - Jan 9, 2019
P4, N=43, Completed, Sponsor: Medical University of South Carolina
N=235 --> 111 Recruiting --> Completed
- | ondansetron / Generic mfg., morphine sulphate / Generic mfg.
Trial completion, Enrollment change: 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=133, Completed, Sponsor: Stanford University
Recruiting --> Completed Active, not recruiting --> Completed | N=76 --> 133
- | Trial completion: BADS: Behavior and Driving Safety Study (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=864, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed | N=76 --> 133 Active, not recruiting --> Completed
- | methadone / Generic mfg.
Phase classification: MTH01: Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal (clinicaltrials.gov) - Dec 24, 2018
P=N/A, N=26, Completed, Sponsor: Kevin Watt
Active, not recruiting --> Completed Phase classification: P1 --> P=N/A
- Trial completion: Acamprosate vs. Placebo in Bipolar Alcoholics (clinicaltrials.gov) - Dec 14, 2018
P4, N=33, Completed, Sponsor: Medical University of South Carolina
Phase classification: P1 --> P=N/A Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: OPAL: "Opiates and PhArmacoLogy" (clinicaltrials.gov) - Dec 12, 2018
P=N/A, N=263, Completed, Sponsor: Nantes University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2016
- | acetylcysteine solution / Generic mfg.
Trial completion, Enrollment change: A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana (clinicaltrials.gov) - Nov 21, 2018
P2, N=116, Completed, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2016 Recruiting --> Completed | N=72 --> 116
- | Chantix (varenicline) / Pfizer
Trial completion, Trial completion date, Trial primary completion date: Tobacco Intervention in Buprenorphine Treatment (clinicaltrials.gov) - Nov 13, 2018
P3, N=175, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=72 --> 116 Active, not recruiting --> Completed | Trial completion date: Apr 2015 --> Dec 2016 | Trial primary completion date: Mar 2015 --> Apr 2016
- | Trial completion, Trial completion date, Trial primary completion date: Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma (clinicaltrials.gov) - Nov 13, 2018
P=N/A, N=60, Completed, Sponsor: University of Lausanne Hospitals
Active, not recruiting --> Completed | Trial completion date: Apr 2015 --> Dec 2016 | Trial primary completion date: Mar 2015 --> Apr 2016 Recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Feb 2018
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings (clinicaltrials.gov) - Nov 2, 2018
P=N/A, N=1080, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Aug 2017 --> Jun 2018 | Trial primary completion date: Mar 2017 --> Jun 2017
- | Phase classification, Enrollment change: Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks (clinicaltrials.gov) - Oct 31, 2018
P1, N=36, Completed, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed | Trial completion date: Aug 2017 --> Jun 2018 | Trial primary completion date: Mar 2017 --> Jun 2017 Phase classification: P2 --> P1 | N=278 --> 36
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Cannabidiol: a Novel Intervention for Cannabis Use Problems? (clinicaltrials.gov) - Oct 24, 2018
P2a, N=82, Completed, Sponsor: University College, London
Phase classification: P2 --> P1 | N=278 --> 36 Active, not recruiting --> Completed | N=168 --> 82 | Trial completion date: Jul 2018 --> Jun 2017 | Trial primary completion date: Jul 2018 --> Feb 2017
- | ondansetron / Generic mfg.
Enrollment change, Trial termination: Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults (clinicaltrials.gov) - Oct 23, 2018
P2, N=74, Terminated, Sponsor: Bankole A. Johnson
Active, not recruiting --> Completed | N=168 --> 82 | Trial completion date: Jul 2018 --> Jun 2017 | Trial primary completion date: Jul 2018 --> Feb 2017 N=300 --> 74 | Completed --> Terminated; Difficulty recruiting target sample
- | trazodone ER / Generic mfg., quetiapine / Generic mfg.
Enrollment change: Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans (clinicaltrials.gov) - Oct 16, 2018
P4, N=1, Terminated, Sponsor: VA Connecticut Healthcare System
N=300 --> 74 | Completed --> Terminated; Difficulty recruiting target sample N=122 --> 1
- | NN1213 / Novo Nordisk
Trial completion: Body-oriented Therapy for Women in SUD Treatment (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=217, Completed, Sponsor: University of Washington
N=122 --> 1 Active, not recruiting --> Completed
- | buprenorphine/naloxone sublingual film / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: NTX-SBX: Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (clinicaltrials.gov) - Oct 11, 2018
P3, N=166, Completed, Sponsor: University of Oslo
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Aug 2016 --> Apr 2018 | Trial primary completion date: May 2016 --> Aug 2016
- | Enrollment change, Trial withdrawal: A Comprehensive Disease Management Program for Medically-Complex Substance Users (clinicaltrials.gov) - Oct 10, 2018
P=N/A, N=0, Withdrawn, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial completion date: Aug 2016 --> Apr 2018 | Trial primary completion date: May 2016 --> Aug 2016 N=100 --> 0 | Recruiting --> Withdrawn
- | NN1213 / Novo Nordisk
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Adherence: Targeting PM to Improve HIV Adherence in Adolescents at Risk for Substance Abuse (clinicaltrials.gov) - Oct 10, 2018
P=N/A, N=104, Completed, Sponsor: Wayne State University
N=100 --> 0 | Recruiting --> Withdrawn Phase classification: P1/2 --> P=N/A | N=194 --> 104 | Trial completion date: Jan 2017 --> Sep 2018 | Trial primary completion date: Jan 2017 --> May 2018
- | Lodonal (naltrexone low dose oral) / Biostax Corp, Statera BioPharma
Enrollment change, Combination therapy: Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana (clinicaltrials.gov) - Sep 14, 2018
P2, N=23, Completed, Sponsor: New York State Psychiatric Institute
Phase classification: P1/2 --> P=N/A | N=194 --> 104 | Trial completion date: Jan 2017 --> Sep 2018 | Trial primary completion date: Jan 2017 --> May 2018 N=49 --> 23
- | Trial completion, Metastases: FIBR-OH: Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease. (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=300, Completed, Sponsor: Rennes University Hospital
N=49 --> 23 Active, not recruiting --> Completed
- | Enrollment closed: Exercise: Addressing Stress in Relapse Prevention for Substance Use Disorders (clinicaltrials.gov) - Aug 31, 2018
P=N/A, N=150, Active, not recruiting, Sponsor: St. Louis University
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- | GET 73 / CT Pharmaceutical Laboratory
Trial completion, Trial completion date, Trial primary completion date: SPAD: Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent (clinicaltrials.gov) - Aug 31, 2018
P1b/2a, N=25, Completed, Sponsor: Laboratorio Farmaceutico Ct S.r.l.
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed | Trial completion date: Nov 2017 --> Feb 2018 | Trial primary completion date: Nov 2017 --> Feb 2018
- | dutasteride capsule / Generic mfg.
Trial completion: Dutasteride Treatment for the Reduction of Heavy Drinking in Men (clinicaltrials.gov) - Aug 31, 2018
P4, N=189, Completed, Sponsor: UConn Health
Recruiting --> Completed | Trial completion date: Nov 2017 --> Feb 2018 | Trial primary completion date: Nov 2017 --> Feb 2018 Active, not recruiting --> Completed
- | aspirin / Generic mfg.
Trial completion date: Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers (clinicaltrials.gov) - Aug 29, 2018
P2, N=54, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial completion date: Sep 2016 --> Feb 2018
- | Phase classification: BIRCWH: Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes (clinicaltrials.gov) - Aug 24, 2018
P2, N=30, Completed, Sponsor: Medical University of South Carolina
Trial completion date: Sep 2016 --> Feb 2018 Phase classification: P=N/A --> P2
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: SF-FASD: Parenting Training for Children With FASD (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=119, Completed, Sponsor: IWK Health Centre
Phase classification: P=N/A --> P2 Recruiting --> Completed | N=200 --> 119
- | morphine sulphate / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) (clinicaltrials.gov) - Aug 15, 2018
P2, N=29, Completed, Sponsor: Mednax Center for Research, Education, Quality and Safety
Recruiting --> Completed | N=200 --> 119 Active, not recruiting --> Completed | N=64 --> 29 | Trial completion date: Apr 2018 --> Oct 2017
- | NN1213 / Novo Nordisk
Trial completion, HEOR: AdolCHICA: Improving Adolescent Health Outcomes Through Preventive Care Transformation (clinicaltrials.gov) - Aug 9, 2018
P=N/A, N=2831, Completed, Sponsor: Indiana University
Active, not recruiting --> Completed | N=64 --> 29 | Trial completion date: Apr 2018 --> Oct 2017 Recruiting --> Completed
- | Trial completion: GMI-IHMDs: Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans (clinicaltrials.gov) - Aug 8, 2018
P=N/A, N=180, Completed, Sponsor: VA Office of Research and Development
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: RRFT: Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=135, Completed, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | clonidine / Generic mfg., dronabinol oral / Generic mfg.
Enrollment change, Trial termination: Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia (clinicaltrials.gov) - Aug 1, 2018
P2/3, N=12, Terminated, Sponsor: Mclean Hospital
Active, not recruiting --> Completed N=18 --> 12 | Recruiting --> Terminated; low enrollment due to limited resources
- | NN1213 / Novo Nordisk
Enrollment change, Trial termination: D-cycloserine (DCS) Pretreatment + CBT + Nicotine Replacement Therapy for Smoking Cessation (DCS) (clinicaltrials.gov) - Aug 1, 2018
P1/2, N=22, Terminated, Sponsor: Mclean Hospital
N=18 --> 12 | Recruiting --> Terminated; low enrollment due to limited resources N=40 --> 22 | Recruiting --> Terminated; left institution protocol closed
- | NN1213 / Novo Nordisk
Enrollment change: Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs) (clinicaltrials.gov) - Jul 31, 2018
P=N/A, N=439, Completed, Sponsor: University of Wisconsin, Madison
N=40 --> 22 | Recruiting --> Terminated; left institution protocol closed N=268 --> 439